IL133585A0 - Soluble prodrugs of paclitaxel - Google Patents

Soluble prodrugs of paclitaxel

Info

Publication number
IL133585A0
IL133585A0 IL13358597A IL13358597A IL133585A0 IL 133585 A0 IL133585 A0 IL 133585A0 IL 13358597 A IL13358597 A IL 13358597A IL 13358597 A IL13358597 A IL 13358597A IL 133585 A0 IL133585 A0 IL 133585A0
Authority
IL
Israel
Prior art keywords
paclitaxel
onium salts
methods
novel
salts
Prior art date
Application number
IL13358597A
Other languages
English (en)
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of IL133585A0 publication Critical patent/IL133585A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
IL13358597A 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel IL133585A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/010746 WO1998058927A1 (en) 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel

Publications (1)

Publication Number Publication Date
IL133585A0 true IL133585A0 (en) 2001-04-30

Family

ID=22261122

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13358597A IL133585A0 (en) 1997-06-20 1997-06-20 Soluble prodrugs of paclitaxel

Country Status (10)

Country Link
EP (1) EP1001769B1 (de)
JP (1) JP2002505682A (de)
AT (1) ATE219363T1 (de)
AU (1) AU3574097A (de)
CA (1) CA2294606A1 (de)
DE (1) DE69713526D1 (de)
HU (1) HUP0002521A3 (de)
IL (1) IL133585A0 (de)
SK (1) SK182599A3 (de)
WO (1) WO1998058927A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777620B2 (en) * 1999-04-09 2004-10-21 Jessie L.S. Au Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6638906B1 (en) 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
JP2004520398A (ja) * 2001-01-18 2004-07-08 ファルマシア・アンド・アップジョン・カンパニー 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
EP2390262A1 (de) 2003-05-16 2011-11-30 Intermune, Inc. Synthetische Chemokinrezeptorliganden und Verwendungsverfahren dafür
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060188508A1 (en) 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
EP2183261A4 (de) 2007-07-03 2010-09-15 Childrens Hosp & Res Ct Oak Polysialylsäurederivate, herstellungsverfahren und anwendungen bei der steigerung von produktion und targeting von krebsantigenen
US9198893B2 (en) 2008-05-22 2015-12-01 Galera Labs, Llc Combination antitumor therapy
WO2010005850A1 (en) 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
CN103607888A (zh) * 2011-04-08 2014-02-26 斯法尔制药私人有限公司 取代的甲基甲酰基试剂以及使用所述试剂改进化合物的物理化学性质和/或药代动力学性质的方法
IN2015DN00552A (de) 2012-07-19 2015-06-26 Redwood Bioscience Inc
CN104884056A (zh) 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法
ES2653487T3 (es) 2013-02-15 2018-02-07 The Regents Of The University Of California Receptor de antígeno quimérico y métodos de uso del mismo
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
DK3107899T3 (da) 2014-02-19 2020-11-16 Aviv Therapeutics Inc Mitokondriel aldehyddehydrogenase 2 (aldh2)-bindende polycykliske amider og anvendelse deraf til cancerbehandling
EP3373977A4 (de) 2015-11-12 2019-07-17 The Board of Trustees of the Leland Stanford Junior University Zellenpenetrierende, guanidiniumreiche oligophosphotriester zur wirkstoff- und sondenfreisetzung
EP3377523A4 (de) 2015-11-19 2019-06-19 The Regents of The University of California Konditionell reprimierbare immunzellenrezeptoren und verfahren zur verwendung davon
EP3231421A1 (de) 2016-04-11 2017-10-18 Greenaltech, S.L. Verwendungen eines carotenoids bei der behandlung oder prävention von durch stress verursachten störungen
KR20180135458A (ko) 2016-04-26 2018-12-20 알.피.쉐러 테크놀러지즈 엘엘씨 항체 컨쥬게이트 및 이의 제조 및 이용 방법
HUE057856T2 (hu) 2016-06-01 2022-06-28 Servier Ip Uk Ltd Polialkilén-oxid-aszparagináz készítményei és eljárás ezek elõállítására és alkalmazására
BR112019014615A2 (pt) 2017-01-18 2020-06-02 F1 Oncology, Inc. Receptores de antígeno quimérico contra axl ou ror2 e métodos de uso dos mesmos
EP3388082A1 (de) 2017-04-13 2018-10-17 Galera Labs, LLC Kombinationskrebsimmuntherapie mit makrocyclischem pentaaza-ringkomplex
CN111902147A (zh) 2018-01-31 2020-11-06 加莱拉实验室有限责任公司 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗
KR20210009315A (ko) 2018-04-11 2021-01-26 오하이오 스테이트 이노베이션 파운데이션 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
EP3946626A1 (de) 2019-04-02 2022-02-09 Kenjockety Biotechnology, Inc. Multispezifische antikörper und zusammensetzungen, reagenzien, kits und verfahren dazu
AU2021214370A1 (en) 2020-01-29 2022-08-18 Kenjockety Biotechnology, Inc. Anti-MDR1 antibodies and uses thereof
AU2021283080A1 (en) 2020-06-04 2022-12-15 Kenjockety Biotechnology, Inc. ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CA3182472A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
KR20230061429A (ko) 2020-09-02 2023-05-08 켄조케티 바이오테크놀러지 인코포레이티드 항-abcc1 항체 및 이의 용도
CA3203652A1 (en) 2020-11-13 2022-05-19 William Robert ARATHOON Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
CA3238353A1 (en) 2021-12-13 2023-06-22 William Robert ARATHOON Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4013595A (en) * 1995-10-27 1997-05-15 Scripps Research Institute, The Method for treating cancer using taxoid onium salt prodrugs
IL132992A0 (en) * 1997-05-27 2001-03-19 Baker Norton Pharma Method and compositions for administering taxanes orally to human patients

Also Published As

Publication number Publication date
AU3574097A (en) 1999-01-04
HUP0002521A2 (hu) 2001-06-28
EP1001769A4 (de) 2000-05-24
EP1001769B1 (de) 2002-06-19
ATE219363T1 (de) 2002-07-15
CA2294606A1 (en) 1998-12-30
DE69713526D1 (de) 2002-07-25
WO1998058927A1 (en) 1998-12-30
SK182599A3 (en) 2000-07-11
JP2002505682A (ja) 2002-02-19
HUP0002521A3 (en) 2002-04-29
EP1001769A1 (de) 2000-05-24

Similar Documents

Publication Publication Date Title
IL133585A0 (en) Soluble prodrugs of paclitaxel
HUT68498A (en) L-dopa ester compositions and process to prepare them
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
RU94045155A (ru) Способы ингибирования болезни альцгеймера
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
MY125821A (en) Pharmaceutical composition of topiramate
AU9189301A (en) Use of substituted imidazo(1,2-A)pyridine-, imidazo(1,2-A)pyrimidine and imidazo(1,2-A)pyrazine-3-YL-amine derivatives for producing NOS-inhibiting medicaments
DK0975595T3 (da) Kokainanaloger
HUT47217A (en) Process for producing pharmaceutical compositions containing indol derivatives as active components
HK1029925A1 (en) Cannabinol-11-oic acid derivatives useful as antiinflammatory agents and analgesics
PL342614A1 (en) Anticarcinogenic drugs
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
BG104983A (en) Aryl fused azapolycyclic compounds
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
MX9704704A (es) Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su obtencion, medicamentos que contienen estos compuestos, y su utilizacion.
MY126998A (en) Substituted pyrroles.
BR9714774A (pt) Pró-drogas solúveis de paclitaxel
JO2360B1 (en) Substituted pyrolates
NO996311L (no) Loeselige forlegemidler av paklitaksel